Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.

The interventional philosophy in glaucoma

“As we turn our sights toward Washington, D.C., for the 2026 ASCRS Annual Meeting, this quarter’s Glaucoma section highlights a significant maturing of the ‘interventional’ philosophy that has come to define our subspecialty,” said Glaucoma Editor Manjool Shah, MD. Read more in his introduction to the section.

Comments Off on The interventional philosophy in glaucoma

Using the Light Adjustable Lens in glaucoma patients

With expanding lens options in cataract surgery and an increase in combined glaucoma and cataract procedures, two ophthalmologists went into detail on when the Light Adjustable Lens (LAL, RxSight) can be a good option for glaucoma patients and considerations when choosing it.

Comments Off on Using the Light Adjustable Lens in glaucoma patients

EyeWorld Weekly, April 3, 2026

➤ Positive topline data from Phase 3 study for thyroid eye disease treatment ➤ Controlled U.S. release of outflow restoration platform for glaucoma ➤ New platform established to help bring supportive evidence to interventional glaucoma ➤ Head-to-head Phase 1b study supports investigational anti-VEGF ➤ Complimentary access to video journal ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, April 3, 2026

EyeWorld Weekly, March 27, 2026

➤ 24-month pivotal data support efficacy of laser treatment for glaucoma ➤ Low-dose atropine drop meets primary, secondary endpoints in new data analysis ➤ Phase 2 topline data for modifier gene therapy for geographic atrophy ➤ Phase 2 data from study evaluating neuropathic corneal pain shows quality of life improvement ➤ New shelf-stable corneal endothelial cell therapy program begins ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, March 27, 2026

EyeWorld Weekly, March 13, 2026

➤ FDA approves new EDOF with limited dysphotopsias ➤ Phase 1/2 12-month data for IOL-based drug delivery system ➤ Topline results from Phase 2a wet AMD study ➤ FDA grants Breakthrough Device Designation to brain implant technology ➤ FDA allows Phase 1/2 trial to begin for investigational cell therapy for familial drusen ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, March 13, 2026

EyeWorld Weekly, February 20, 2026

➤ Positive results in Phase 3 superiority trial for wet AMD treatment ➤ Dosing begins for first-in-human myopia prevention drop ➤ Pre-NDA meeting with FDA for IOP-lowering drop ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 20, 2026

EyeWorld Weekly, February 6, 2026

➤ New drop for temporary presbyopia relief approved ➤ First-in-human results for accommodating IOL ➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy ➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 6, 2026